更新于：2024-05-01
Doxapram Hydrochloride
盐酸多沙普仑
更新于：2024-05-01
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1965-06-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C24H33ClN2O3 |
InChIKeyZOMBFZRWMLIDPX-UHFFFAOYSA-N |
CAS号7081-53-0 |
查看全部结构式(2)
关联
21
项与 盐酸多沙普仑 相关的临床试验Comparison of the effectiveness and speed of shivering treatment after general anesthesia with pethidine and doxapram in patients undergoing orthopedic surgery and urological surgery referred to Firoozgar Hospital in Tehran.
Doxapram Versus Placebo in Preterm Newborns: An International Double Blinded Multicenter Randomized Controlled Trial
Doxapram versus placebo in preterm newborns: an international double blinded multicenter randomized controlled trial. - Doxa TRIAL
100 项与 盐酸多沙普仑 相关的临床结果
登录后查看更多信息
100 项与 盐酸多沙普仑 相关的转化医学
登录后查看更多信息
100 项与 盐酸多沙普仑 相关的专利（医药）
登录后查看更多信息
541
项与 盐酸多沙普仑 相关的文献（医药）2024-01-16Archives of disease in childhood. Fetal and neonatal edition
Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5-6 years.
Article
作者: Ludovic Tréluyer ; Elodie Zana-Taieb ; Pierre-Henri Jarreau ; Valérie Benhammou ; Pierre Kuhn ; Mathilde Letouzey ; Laetitia Marchand-Martin ; Wes Onland ; Véronique Pierrat ; Lauren Saade ; Pierre Yves Ancel ; Héloïse Torchin
OBJECTIVE:
To assess the long-term neurodevelopmental impact of doxapram for treating apnoea of prematurity.
DESIGN:
Secondary analysis of the French national cohort study EPIPAGE-2. Recruitment took place in 2011. A standardised neurodevelopmental assessment was performed at age 5-6 years. A 2:1 propensity score matching was used to control for the non-randomised assignment of doxapram treatment.
SETTING:
Population-based cohort study.
PATIENTS:
All children born before 32 weeks' gestation alive at age 5-6 years.
INTERVENTIONS:
Blind and standardised assessment by trained neuropsychologists and paediatricians at age 5-6 years.
MAIN OUTCOME MEASURES:
Neurodevelopmental outcomes at age 5-6 years assessed by trained paediatricians and neuropsychologists: cerebral palsy, developmental coordination disorders, IQ and behavioural difficulties. A composite criterion for overall neurodevelopmental disabilities was built.
RESULTS:
The population consisted of 2950 children; 275 (8.6%) received doxapram. Median (IQR) gestational age was 29.4 (27.6-30.9) weeks. At age 5-6 years, complete neurodevelopmental assessment was available for 60.3% (1780 of 2950) of children and partial assessment for 10.6% (314 of 2950). In the initial sample, children receiving doxapram had evidence of greater clinical severity than those not treated. Doxapram treatment was associated with overall neurodevelopmental disabilities of any severity (OR 1.43, 95% CI 1.07 to 1.92, p=0.02). Eight hundred and twenty-one children were included in the 2:1 matched sample. In this sample, perinatal characteristics of both groups were similar and doxapram treatment was not associated with overall neurodevelopmental disabilities (OR 1.09, 95% CI 0.76 to 1.57, p=0.63).
CONCLUSIONS:
In children born before 32 weeks' gestation, doxapram treatment for apnoea of prematurity was not associated with neurodevelopmental disabilities.
2023-12-22Journal of clinical medicine
Clinical Dilemma Involving Treatments for Very Low-Birth-Weight Infants and the Potential Risk of Necrotizing Enterocolitis: A Narrative Literature Review.
Review
作者: Shigeo Iijima
Necrotizing enterocolitis (NEC) is a critical gastrointestinal emergency with substantial morbidity and mortality risks, especially for very low-birth-weight (VLBW) infants, and unclear multifactorial pathophysiology. Whether common treatments for VLBW infants increase the NEC risk remains controversial. Indomethacin (utilized for patent ductus arteriosus) offers benefits but is concerning because of its vasoconstrictive impact on NEC susceptibility. Similarly, corticosteroids used to treat bronchopulmonary dysplasia may increase vulnerability to NEC by compromising immunity and altering the mesenteric blood flow. Histamine-2 receptor blockers (used to treat gastric bleeding) may inadvertently promote NEC by affecting bacterial colonization and translocation. Doxapram (used to treat apnea) poses a risk of gastrointestinal disturbance via gastric acid hypersecretion and circulatory changes. Glycerin enemas aid meconium evacuation but disrupt microbial equilibrium and trigger stress-related effects associated with the NEC risk. Prolonged antibiotic use may unintentionally increase the NEC risk. Blood transfusions for anemia can promote NEC via interactions between the immune response and ischemia-reperfusion injury. Probiotics for NEC prevention are associated with concerns regarding sepsis and bacteremia. Amid conflicting evidence, this review unveils NEC risk factors related to treatments for VLBW infants, offers a comprehensive overview of the current research, and guides personalized management strategies, thereby elucidating this clinical dilemma.
2023-11-18Seminars in fetal & neonatal medicine
Improving rates of successful extubation: Medications.
Review
作者: Matteo Bruschettini
This chapter focuses on the pharmacological management of newborn infants in the peri-extubation period to reduce the risk of re-intubation and prolonged mechanical ventilation. Drugs used to promote respiratory drive, reduce the risk of apnoea, reduce lung inflammation and avoid bronchospasm are critically assessed. When available, Cochrane reviews and randomised trials are used as the primary sources of evidence. Methylxanthines, particularly caffeine, are well studied and there is accumulating evidence to guide clinicians on the timing and dosage that may be used. Efficacy and safety for doxapram, steroids, adrenaline and salbutamol are summarised. Management of term infants, extubation following surgery, accidental and complicated extubation and the use of cuffed endotracheal tubes are presented. Overall, caffeine is the only drug with a substantial evidence base, proven to increase the likelihood of successful extubation in preterm infants; no drugs are needed to facilitate extubation in most term infants. Future studies might further define the role of caffeine in late preterm infants and evaluate medications for post-extubation stridor, bronchospasm or apnoea not responsive to methylxanthines.
3
项与 盐酸多沙普仑 相关的新闻（医药）2023-03-14
一致性评价
2023-01-07
2022-09-05
100 项与 盐酸多沙普仑 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 呼吸暂停 | 批准上市 | 日本 更多 | |
| 呼吸功能不全 | 批准上市 | 印度 更多 | - |
| 肺部疾病 | 批准上市 | 美国 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 呼吸暂停 三线 | 85 | Doxapram dosing adjusted for gender and postmenstrual age (GrA) | (膚顧衊遞淵構獵製窪壓) = 願艱範築夢鏇醖憲遞醖 襯鑰鹽鑰積繭遞積築窪 (鹽壓積選遞蓋構鏇醖選 ) | - | 2016-12-01 | |
(Infants' weight alone (GrW)) | (膚顧衊遞淵構獵製窪壓) = 壓襯築鹹網製觸構簾獵 襯鑰鹽鑰積繭遞積築窪 (鹽壓積選遞蓋構鏇醖選 ) | ||||||
临床2期 | 49 | Inhaled placebo+IV doxapram (RCT Placebo) | 顧鏇鹹顧鹽築鹽醖艱鹹(積淵膚齋艱膚膚遞遞襯) = 艱膚繭製鏇願鏇遞簾製 壓糧餘餘廠窪範遞膚鹽 (顧淵壓鹽醖鑰鏇獵選鹹, 齋構願製製蓋夢淵簾觸 ~ 鹹願觸積網憲鹽鏇艱鬱) 更多 | - | 2017-06-16 | ||
(RCT Alprazolam 1 mg) | 顧鏇鹹顧鹽築鹽醖艱鹹(積淵膚齋艱膚膚遞遞襯) = 積衊糧觸獵網繭製廠範 壓糧餘餘廠窪範遞膚鹽 (顧淵壓鹽醖鑰鏇獵選鹹, 獵窪鹽遞艱繭簾糧淵艱 ~ 壓觸觸積製願蓋簾簾範) 更多 | ||||||
N/A | - | - | 蓋齋簾鑰夢鏇膚鑰選醖(齋構鬱鏇膚夢鏇齋築簾) = 簾選糧鹹糧鬱顧網衊鹹 願糧夢艱遞壓窪齋襯簾 (蓋醖廠醖憲顧淵艱衊築 ) 更多 | - | 2022-08-27 | ||
Ketodoxapram | 蓋齋簾鑰夢鏇膚鑰選醖(齋構鬱鏇膚夢鏇齋築簾) = 網範憲鏇艱淵鏇蓋範蓋 願糧夢艱遞壓窪齋襯簾 (蓋醖廠醖憲顧淵艱衊築 ) 更多 | ||||||
N/A | - | 製獵鹽願窪衊願鏇廠夢(簾觸廠鹹積範糧網憲蓋) = 窪鑰衊糧壓鬱廠鑰襯憲 築膚襯憲齋艱糧齋窪壓 (獵淵簾蓋蓋壓鑰簾糧顧 ) | - | 2019-09-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用